Hossein Hemmati - Razi Clinical Research Development Unit, Guilan University of Medical Sciences Rasht Iran
Mohammad Taghi Ashoobi - Razi Clinical Research Development Unit, Guilan University of Medical Sciences Rasht Iran
Mostafa Golshekan - Guilan Road Trauma Research Center, Guilan University of Medical Sciences Rasht Iran

Blood clots are one of the leading causes of death as a consequence of cardiovascular disease in the first place. Design and synthesis of new thrombolytic drugs is aimed at the prevention of side effects one of the important target in medicine. Herein, we report a novel nanocomposite prepared by urokinase with magnetite nanoparticles (Fe۳O۴@MCM-۴۱-Urokinase).The magnetic nano-drug was prepared in three steps: (i) preparation of colloidal iron oxide magnetite nanoparticles (Fe۳O۴MNPs) with particle size lower than ۸.۰ nm, (ii) development of an organic–inorganic MCM-۴۱ mesoporous structure on the surface of MNPs (Fe۳O۴@MCM-۴۱) and (iii) load the Urokinase on synthesized nano-composite sueface (Fe۳O۴@MCM-۴۱-Urokinase). The prepared organic–inorganic magnetic nano-drug was characterized by Fourier transform infrared spectroscopy (FT-IR), X-ray powder diffraction (XRD), transmission electron microscopy (TEM), N۲ adsorption–desorption and energy-dispersive X-ray (EDX) techniques. Finally, drug delivery was tested in rats

Thrombolytic agent, Magnetic nano-particles, Drug delivery